Shanghai Ji Xing Pharma in-licensed China rights to a heart failure treatment from Cytokinetics of South San Francisco in a $400 million pact. Ji Xing will own Greater China rights for omecamtiv mecarbil to treat heart failure with reduced ejection fraction. Cytokinetics will receive $70 million, consisting of $50 million from Ji Xing in upfront and near-term payments and a $20 million investment from RTW Investments, Ji Xing's backer. Cytokinetics will also be eligible for up to $330 million in milestone payments plus royalties. More details.... Stock Symbol: (NSDQ: CYTK) Share this with colleagues: // //